Bright Minds Biosciences Inc. - common stock (DRUG)
26.20
-28.78 (-52.35%)
NASDAQ · Last Trade: Nov 2nd, 6:54 PM EST
News & Press Releases
US Session Top Gainers and Losers Led by INLF and AUROWchartmill.com
Via Chartmill · November 2, 2026
Small-Cap Market Movers: Top Gainers and Losers on Nov. 2, 2026chartmill.com
Via Chartmill · November 2, 2026
US Gap Movers: Top Gap-Up and Gap-Down Stocks in Today's Sessionchartmill.com
Via Chartmill · November 2, 2026
Premarket Movers Nov. 2, 2026: Gainers and Loserschartmill.com
Via Chartmill · November 2, 2026
Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies
NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that the U.S. Food and Drug Administration (“FDA”) has notified the Company via email that its investigational new drug application (“IND”) for Developmental and Epileptic Encephalopathies (“DEEs”) and related Protocol BMB-101-105 has been placed on a partial clinical hold following the FDA’s review.
By Bright Minds Biosciences · Via GlobeNewswire · November 2, 2026
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, October 7-8, and the PWS Family Conference, October 9-10, at the Marriott Philadelphia Downtown.
By Bright Minds Biosciences · Via GlobeNewswire · September 30, 2026
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1fool.com
Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases.
Via The Motley Fool · May 26, 2026
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:
By Bright Minds Biosciences · Via GlobeNewswire · May 26, 2026
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipelinefool.com
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.
Via The Motley Fool · May 21, 2026
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buyfool.com
This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.
Via The Motley Fool · May 16, 2026
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive agreement to acquire Celeno Therapeutics (NASDAQ: SLNO). The all-cash transaction, valued at approximately $2.9 billion, underscores a strategic push
Via MarketMinute · April 7, 2026
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today closed its recently announced public offering of 1,945,000 common shares in the capital of the Company (the “Common Shares”) at a price of US$90.00 per Common Share for gross proceeds of US$175,050,000 (the “Offering”). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities sold in this Offering were offered by Bright Minds.
By Bright Minds Biosciences · Via GlobeNewswire · January 9, 2026
The market is filled with gapping stocks in Wednesday's session.chartmill.com
Via Chartmill · January 7, 2026
Traders are paying attention to the gapping stocks in Tuesday's session.chartmill.com
Via Chartmill · January 6, 2026
Why Did DRUG Stock Rocket 51% Today?stocktwits.com
The Phase 2 BREAKTHROUGH trial met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.
Via Stocktwits · January 6, 2026
Stay updated with the stocks that are on the move in today's pre-market session.chartmill.com
Via Chartmill · January 6, 2026
Why Bright Minds Biosciences Stock Topped the Market on Mondayfool.com
The company isn't wasting any time drafting seasoned professionals to help it develop medication for a rare genetic disorder.
Via The Motley Fool · November 17, 2025
Large Patient Population Is Key Driver For Bright Minds' Growthbenzinga.com
BTIG initiates coverage on Bright Minds Biosciences with a Buy rating, citing BMB‑101's potential and key Phase 2 data expected by the end of 2025
Via Benzinga · September 8, 2025
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upsidebenzinga.com
Chardan initiates Bright Minds with a Buy rating, citing over $1 billion sales potential for epilepsy drug BMB-101 despite limited clinical data.
Via Benzinga · May 7, 2025
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
– Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in epilepsy drug development and research to support Company’s clinical focus on epilepsy –
By Bright Minds Biosciences · Via GlobeNewswire · March 4, 2025
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and select members of senior management, will participate in three healthcare conferences, as follows:
By Bright Minds Biosciences · Via GlobeNewswire · February 24, 2025
Biotechs on the Brink: 2 Stocks With Huge Potential
BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.
Via MarketBeat · February 14, 2025
This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursdaybenzinga.com
Via Benzinga · January 23, 2025
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy --
By Bright Minds Biosciences · Via GlobeNewswire · January 7, 2025
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
- Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data -
By Bright Minds Biosciences · Via GlobeNewswire · November 21, 2024